Goldenwell Biotech Reports Near-Zero Revenue, Widening Losses for FY 2025
GWLL has more than doubled off its 52-week low of $0.059.
Summary
Goldenwell Biotech reported extremely poor FY 2025 results, with revenue plummeting to just $55 and net loss widening significantly to $296,471, resulting in an EPS of $(2.99). This annual filing follows a series of restated quarterly financials for Q1, Q2, and Q3 2025, which previously highlighted accounting errors, ineffective disclosure controls, and a severe going concern warning. The results confirm the company's dire financial state, showing virtually no commercial traction and rapidly expanding losses. Management expects current cash to last only until December 2026 and plans to seek further equity funding to support operations and planned manufacturing facility construction.
At the time of this announcement, GWLL was trading at $0.52 on OTC in the Life Sciences sector, with a market capitalization of approximately $51.5M. The 52-week trading range was $0.06 to $10.00. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.